Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

FDA Grants Fast Track Status to Immunotherapy GEN-1 in Advanced Ovarian Cancer

February 22nd 2021

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Coleman Looks Forward to a Big Year for New Cervical Cancer Therapies

February 15th 2021

Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.

FDA Approval Sought for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

February 11th 2021

February 10, 2021 - A biologics license application has been submitted to the FDA for the accelerated approval of the antibody-drug conjugate tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

Promising Novel Targets for Endometrial Cancer Management

February 4th 2021

Novel Strategies in Development for EC Management

February 4th 2021

Therapy Sequencing Through Multiple Lines of Therapy in EC

February 4th 2021

Impact of Pembrolizumab/Lenvatinib Approval in EC

February 4th 2021

Safety/Efficacy Results From EC Cohort of KEYNOTE-146

February 4th 2021

Rationale for Combination Therapy in Advanced EC

February 4th 2021

GARNET Clinical Trial Regimen in Advanced Disease

February 4th 2021

Second-Line Checkpoint Inhibitor for MSI-H Disease

February 4th 2021

Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

February 4th 2021

Treatment Challenges: Advanced Endometrial Cancer

February 4th 2021

Genomic Assessments for Metastatic Disease

January 29th 2021

Endometrial Cancer Incidence and Risk Classification

January 29th 2021

Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer

January 28th 2021

Dr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

January 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

HPV-Negative Cervical Cancer: Myth or An Area to Therapeutically Tackle?

January 20th 2021

The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

January 18th 2021

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.